Loading
ACR-2316 is an experimental small molecule from Acrivon Therapeutics, in phase 1 trials for lung cancer, endometrial cancer and cervical cancer and other cancers.
ACR-2316 is a small molecule (oral) from Acrivon Therapeutics. A selective dual inhibitor of WEE1 and PKMYT1 that Acrivon designed with its AP3 phosphoproteomics platform. Its furthest stage is phase 1, for lung cancer, endometrial cancer, cervical cancer and oesophago-gastric junction cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 study moved into randomised dose expansion (Q2 2026 results release, 12 August 2026). Registry phase PHASE1/PHASE2, RECRUITING. Stage given as phase-1 because the study is phase 1/2 and is in dose expansion. Whether it works in people has not been established unless a trial below reports it.
A selective dual inhibitor of WEE1 and PKMYT1 that Acrivon designed with its AP3 phosphoproteomics platform. Connects to WEE1.
1.ACR-2316 slips into a pocket on WEE1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ACR-2316" OR ABSTRACT:"ACR-2316") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ACR-2316, not a curated reading list.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares WEE1 and the tag pipeline.
Shares Acrivon Therapeutics and the tag pipeline.
Shares WEE1 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/